Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies

Fig. 2

Time to resolution of enthesitis in patients with enthesitis at baseline. Data shown for overall population (A), TNFi-naïve (B), and TNFi-IR (C) subpopulations. Percentages of patients with resolution at weeks 16, 52, and 104 were derived as 1 minus the survival function at days 112, 365, and 729, respectively (Kaplan-Meϊer plot). Placebo patients were censored at day 168 of follow-up. IR, inadequate responder; SEC, secukinumab; TNFi, tumor necrosis factor inhibitor

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us